Endonovo Therapeutics, Inc.
ENDV· OTC
ENDVEndonovo Therapeutics, Inc.
Filed Aug 19, 2014 · 10-Q · 50 days after period end · 0001469709-14-000358
| Metric | Q2 2014 | Q2 2013 | Q2 2012 |
|---|---|---|---|
| Revenue | $16.42K | $0.00 | $8.09K |
| Net Income | -$202.68K | -$639.99K | -$430.61K |
| EPS Diluted | $0.26 | -$0.01 | -$0.01 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
ended Jun 30, 2014 · filed Aug 19, 2014 · 50 d after period end
